We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Positive Lymphocyte Gene Rearrangement Evaluated for Hematologic Malignancies

By LabMedica International staff writers
Posted on 08 Sep 2020
The diagnosis of a lymphoid malignancy requires the establishment of monoclonality of a lymphocyte population through morphologic assessment and laboratory testing, such as flow cytometry, immunohistochemistry, and cytogenetic analysis.

These methods can yield conflicting results, however, and in up to 15% of cases of suspected lymphoid malignancies, molecular assessment of immunoglobulin (IG) and/or T-cell receptor (TCR) gene rearrangements is necessary to confirm a diagnosis. More...
the presence of a population of B or T cells with the same gene rearrangement pattern is highly supportive of lymphoid malignancy.

Medical scientists at the Yale School of Medicine (New Haven, CT, USA) extracted data from medical records of patients who underwent IG or TCR gene rearrangement testing at an affiliated hospital from January 1, 2013 to July 6, 2018. Date of testing, specimen source, and morphologic, flow cytometric, immunohistochemical, and cytogenetic characterization of the tissue source were recorded. Gene rearrangement results were categorized as test positive/phenotype positive (T+/P+), test positive/phenotype negative (T+/P−), test negative/phenotype negative (T−/P−), or test negative/phenotype positive (T−/P+) based on comparison to other studies and/or final diagnosis. Patient records were reviewed for subsequent diagnosis of hematologic malignancy for patients with positive gene rearrangements, but no other evidence for a disease process.

The authors reported that a total of 136 patients with 203 gene rearrangement studies were analyzed. For TCR studies, there were two T+/P− and one T−/P+ results in 47 peripheral blood (PB) assays, as well as seven T+/P− and one T−/P+ results in 54 bone marrow assays. Regarding IG studies, three T+/P− and 12 T−/P+ results in 99 bone marrow (BM) studies were identified. None of the 12 patients with T+/P− TCR or IG gene rearrangement studies later developed a lymphoproliferative disorder.

The 12 T/Pþ IG studies included four cases of multiple myeloma (MM), three cases of monoclonal gammopathy of undetermined significance, one case of low-grade B-cell non-Hodgkin’s lymphoma, one case of monoclonal B-cell lymphocytosis, one case of low-grade B–non-Hodgkin’s lymphoma plus MM, one case of low-grade B–non-Hodgkin’s lymphoma plus myelodysplastic syndrome, and one case of monoclonal gammopathy of undetermined significance plus adult T-cell leukemia/lymphoma. The two T/Pþ TCR studied corresponded to one diagnosis of T-cell acute lymphoblastic leukemia and one diagnosis of T-cell large granular lymphocytic leukemia.

The authors concluded that the results from the present study suggest positive IG/TCR gene rearrangement studies are not predictive of lymphoproliferative disorders in the context of otherwise negative BM or PB findings. As such, when faced with equivocal pathology reports, clinicians can be practically advised that isolated positive IG/TCR gene rearrangement studies do not indicate a need for closer surveillance. The study was published on July 31, 2020 in the journal Archives of Pathology & Laboratory Medicine.

Related Links:
Yale School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.